Introduction
Laninamivir octanoate (LO, Fig. 1 ), a long-acting neuraminidase inhibitor, has been licensed in Japan for the treatment of influenza virus infection in both adult and pediatric patients. In a double-blind, randomized controlled clinical trial in adult patients with infection of seasonal influenza viruses including oseltamivir-resistant viruses, a single inhaled 40 mg dose of LO had a non-inferior efficacy compared with oseltamivir (75 mg) which was administered orally twice daily over 5 days (Watanabe et al. 2010) . In addition, a single dose of LO markedly reduced the time to alleviation of influenza illness in comparison with oseltamivir, in pediatric patients infected with oseltamivir-resistant influenza A (H1N1) virus (Sugaya et al. 2010) .
LO is an octanoyl ester prodrug of the active form laninamivir (Fig. 1) , which shows potent neuraminidase inhibitory activities in vitro against various influenza A and B viruses, including oseltamivir-resistant viruses (Yamashita et al. 2009 ), 2009 pandemic H1N1 viruses (Itoh et al. 2009 ), and highly pathogenic H5N1 influenza viruses (Kiso et al. 2010) . In a mouse influenza virus A/Puerto Rico/8/34 infection model, the intranasal dose of laninamivir demonstrated a prolonged survival effect, and this effect was drastically improved by derivatization into the octanoyl ester prodrug, LO (Yamashita et al. 2009 , Honda et al. 2009 ). In the same model, a single intranasal dose of LO showed an antiviral effect which is similar to that after the repeated intranasal dose of zanamivir and superior to that after the repeated oral dose of oseltamivir (Kubo et al. 2010 ).
These long-acting characteristics of LO can be partly explained by the following favorable pharmacokinetic property. After a single intranasal/intratracheal administration
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This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 22, 2012 as DOI: 10.1124 at ASPET Journals on April 18, 2017 dmd.aspetjournals.org Downloaded from of LO to mice and rats, the LO was efficiently converted/hydrolyzed to its active form laninamivir, and thereafter the generated laninamivir was retained over long periods in the respiratory tissues (Koyama et al. 2009 , Koyama et al. 2010 . Moreover, it was confirmed in mice that this retention level was much higher than those after intranasal administration of laninamivir itself and zanamivir (Koyama et al. 2009 ). Such preferable pharmacokinetic characteristics were observed in humans as well. After a single inhaled administration of LO in healthy male volunteers, plasma laninamivir reached a C max at 4 h and then slowly decreased with an elimination half-life (t 1/2 ) of approximately 3 days (Ishizuka et al. 2009 , Yoshiba et al. 2011 ). Furthermore, highly retained laninamivir was confirmed in the pulmonary epithelial lining fluid (ELF) with a longer t 1/2 than that observed in the plasma (Ishizuka et al. 2012 ).
The ELF is a thin layer that covers the airway surface and is often considered to be the extracellular site of pulmonary infections (Baldwin et al. 1992) . Bronchoalveolar lavage (BAL) has become a widely used technique for collecting the ELF in order to determine sufficient drug concentrations achieved at the infected site. This technique has been commonly applied to antibacterial agents (Rodvold et al. 2011a) and is also recently applicable to other anti-infective agents such as antifungal, antitubercular, antiparasitic, and antiviral agents (Rodvold et al. 2011b ). In the case of LO as well, it is likely that the ELF is a relevant site to determine drug concentrations from the standpoint of PK/PD relationship, considering viral surface location of the neuraminidase enzyme.
In the present study, we investigated intrapulmonary pharmacokinetics and disposition after a single intranasal administration of LO in mice utilizing the BAL technique and microautoradiography, in comparison with that after a single intranasal 6 administration of the active form, laninamivir. Furthermore, we examined the LO transport and subsequent conversion/hydrolysis into laninamivir in primary cultured mouse lung epithelial cells, with a corresponding compartmental kinetic analysis in order to investigate the prolonged high retention mechanism of laninamivir in the respiratory tissues after intranasal administration of LO.
This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 22, 2012 as DOI: 10.1124 at ASPET Journals on April 18, 2017 dmd.aspetjournals.org Downloaded from compound (LO or laninamivir) dissolved in physiological saline at 0.2 μ mol/ml was administered intranasally to the mice at a volume of 2.5 ml/kg, corresponding to 0.5 μ mol/kg (N=3-4/time point). At designated time points up to 24 h post-dose, blood was collected by cardiac puncture under diethyl ether anesthesia. Subsequently, the trachea was surgically exposed and cannulated with a polyethylene tube attached to a guide needle on a 1-ml syringe. Three 1-ml aliquots of phosphate buffered saline (pH 7.4) were slowly instilled through the trachea into the airway space, and bronchoalveolar lavage (BAL) fluid was collected by gentle aspiration. After that, whole lung was isolated from each carcass. To minimize further hydrolysis of LO after the sample collection, the protease inhibitor AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) was added to each of the blood and BAL fluids at the final concentration of 5 mM. The blood was then centrifuged at 18800g for 3 min at 4°C to obtain plasma, and the BAL fluid was centrifuged at 650g for 10 min at 4°C to remove cells and debris. The lungs that were individually weighed were added to 9-fold volume of 50% acetonitrile and homogenized using a Mixer Mill MM300 (Retsch GmbH, Haan, Germany) to prepare a 10% lung homogenate. All of the samples were stored frozen at −20°C until analysis. MRM mode using the mass transitions of m/z 347→60 and 350→60, respectively. The calibration curves were generated using the analyte to IS peak area ratios by weighted
Determination
(1/x) least-squares linear regression over the concentration ranges of 1-100 ng/ml (2.12-212 pmol/ml) and 0.5-100 ng/ml (1.44-288 pmol/ml) for LO and laninamivir, respectively. Intra-assay precision and accuracy were less than 15% for the quality control samples prepared at low, medium and high concentrations of each analyte. Some of the samples were diluted with blank matrices to fall within the calibration curve range described above.
Urea assay. In order to correct the dilution of ELF by BAL fluid, both BAL fluid and plasma were tested for urea concentration using a commercially available urea assay kit (Urea Nitrogen B test kit, Wako Pure Chemical Industries, Ltd.). The BAL fluid was analyzed undiluted, whereas the plasma was diluted 1:5 with distilled water to fall within the calibration curve range (0.5-10 mg/dL). Based on the urea concentrations determined, drug concentrations in ELF (C ELF ) were calculated from the following formula:
where C BAL is the measured drug concentration in BAL fluid, Urea plasma is the urea concentration in plasma, and Urea BAL is the urea concentration in BAL fluid. This calculation is based on the assumption that urea concentrations in the vascular and ELF compartments are equivalent because of the freely diffusible nature of urea (Rennard SI et al. 1992 ).
Pharmacokinetic analysis. The pharmacokinetic parameters of LO and laninamivir were calculated from the ELF, lung and plasma concentrations using Phoenix WinNonlin (Version 6.1; Pharsight Corp., Mountain View, CA) based on a non-compartmental method.
The maximum concentration (C max ) and the time to C max (T max ) were obtained by observation. The elimination half-life (t 1/2 ) was calculated by the regression analysis of 3 or more log-transformed data points in the terminal phase. The area under the concentration versus time curve up to the last quantifiable time (AUC last ) was calculated by the trapezoidal method.
Microautoradiography. [
14 C]LO was administered intranasally to mice, in a similar manner as described above. At 0.25, 1, 6, and 24 h (N=1/time point), the mice were sacrificed by exsanguination under anesthesia with diethyl ether. The bronchi and lungs were excised as representatives of the respiratory tissues, and then fixed in 10% neutral buffered formalin. The formalin-fixed tissues were dehydrated in ethanol, transferred to xylene, and embedded in paraffin. The paraffin sections were cut at 4-μm thickness on a microtome (Yamato Kohki Industrial Co., Ltd., Saitama, Japan) and the slices were mounted on MAS-coated slides (Matsunami Glass Ind., Ltd., Osaka, Japan). After
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Drug uptake assay. The cells grown on the 12-well plate were washed twice with Ham's F12-K medium (without serum and additives), and pre-incubated in the medium (1 ml/well) for 30 min at 37°C. For the time course of LO uptake into the cells, 50
dissolved in the medium (1 ml/well) was added to each well and incubated up to 120 min at 37°C in a 5% CO 2 incubator. For concentration dependency of the LO uptake, 10−1000 μ M LO (1 ml/well) was added and incubated in a similar manner. After the incubation, the cells were washed three times with 3 ml of ice-cold phosphate buffered saline (pH 7.4) and then solubilized with 0.5% (v/v) Triton X-100 (0.2 ml/well). All of the solubilized samples were subjected to the determination of intracellular LO and laninamivir by LC-MS/MS as described above. Protein concentrations in the samples were determined by the Lowry method using bovine serum albumin as a standard. All of the assays were conducted in triplicate.
Drug release and disposition assay. After cells were incubated with 50 μM LO (1 ml/well) for 60 min, the cells were washed three times with 3 ml of pre-warmed medium and subsequently further incubated with drug-free medium at 37°C in the 5% CO 2 incubator. At designated time points, all of the medium was collected from each well and
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All of the medium and solubilized cell samples were subjected to the LC-MS/MS analysis.
Protein concentrations in the cell samples were also determined by the Lowry method.
Compartmental kinetic modeling. Based on the drug release assay data in the primary cultured mouse airway epithelial cells, compartmental kinetic modeling was performed using nonlinear ordinary least-squares regression. The regression and parameter estimation were achieved using Phoenix WinNonlin, and the model was simultaneously fitted to data of the drug release experiment. Model scheme is shown in Fig. 6 , which was developed to estimate rate constants describing the following events: the release of intracellular LO into the extracellular compartment (k LO ), hydrolysis of LO to laninamivir within the intracellular compartment (k Hydrolysis ), and release of intracellular laninamivir into the extracellular compartment (k Lani ). Equations used to fit the model to the data set are shown below.
where LO M and LO C are the concentration of LO in the medium and cells, respectively, and Lani M and Lani C are the concentration of laninamivir in the medium and cells, respectively. The uptake transport rates of LO and laninamivir were considered as zero in
This article has not been copyedited and formatted. The final version may differ from this version. this model, since the drug-free medium was newly exchanged at each time point, therefore drug concentration in the medium was quite low compared to that in the cells. All of the rate constants in this model were assumed to be first order.
This article has not been copyedited and formatted. The final version may differ from this version. Pharmacokinetic parameters of LO and/or laninamivir for each administration are listed in Table 1 . After LO administration, ELF concentration of LO rapidly decreased with a t 1/2 of 1.1 h, whereas that of laninamivir reached a C max (1520 pmol/ml) at 1 h post-dose and then slowly declined with a t 1/2 of 25.1 h. In a similar fashion, lung concentration of LO rapidly declined, while that of laninamivir was observed soon after administration with C max (4350 ng/g) being reached at 6 h post-dose, followed by being gradually eliminated with a t 1/2 of 30.9 h. In plasma, LO appeared rapidly with a t max of 0.5 h and decreased with a t 1/2 of 0.6 h. Plasma laninamivir reached a C max at 1 h post-dose and then eliminated in a bi-exponential manner with a terminal t 1/2 of 13.1 h. Among the biological fluids and tissues tested, the lungs exhibited the highest retention level of laninamivir, being 2680
pmol/g at the final time point (24 h).
On the other hand, after laninamivir administration, laninamivir in ELF decreased with more rapid elimination rate than LO administration and fell down to a concentration of 51.3 pmol/ml at 4 h post-dose, which was approximately 7-and 22-fold lower than LO and laninamivir concentrations (348 and 1150 pmol/ml) at the same time point after LO administration, respectively. Subsequently, ELF concentration of laninamivir gradually
This article has not been copyedited and formatted. The final version may differ from this version. concentration reached a C max at 0.5 h post-dose and then declined over time, not being detected after 8 h post-dose. When comparing the lung retention levels at 24 h between the two test compounds administered, laninamivir concentration was 9.5-fold higher in LO administration than laninamivir administration. Similarly, laninamivir concentrations in both ELF and plasma were quite higher in LO administration, compared with laninamivir administration.
Microautoradiographic localization in the respiratory tissues after intranasal administration of [ 14 C]LO. After a single intranasal administration of [
14 C]LO to mice, the localization of radioactivity in the respiratory tissues was investigated at a cellular level by microautoradiography, using both bronchi and lungs as representatives. At 0.25 h post-dose, the radioactivity detected as black-silver grains was confirmed to be widely distributed in the airway space and epithelial layer of both tissues (data not shown).
Thereafter, the [ 14 C]LO-derived radioactivity was clearly present for a long period, as shown representatively in the microautoradiograms at 24 h post-dose (Fig. 4) . In the bronchi (Fig. 4A) , the radioactivity was mainly located on the epithelial cells (ciliated columnar epithelial cells and goblet cells), and also observed on the bronchial gland to some extent. In the lungs (Fig. 4B) , a distinct radioactivity was seen over the epithelial cells (cuboidal epithelial cells) of bronchioli, terminal bronchiole, and/or alveolar bronchiole. A slight level of radioactivity was detected on the pulmonary alveoli and pulmonary arterial blood as well.
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Discussion
These experiments represent that a prolonged high retention of laninamivir in the respiratory tissues could be achieved by utilizing a prodrug approach and that the airway epithelial cells were considered to be an important component involved in this retention.
Furthermore, a potential mechanism of such a high retention is proposed based on in vivo and in vitro studies.
After a single intranasal administration of LO (0.5 μmol/kg), the active metabolite laninamivir was measureable in ELF, lungs and plasma shortly after dosing (2 min), and the elimination of laninamivir was considerably slow over the t 1/2 range of 13.1 to 30.9 h ( Fig. 2 and Table 1 ). Among the biological fluids and tissues analyzed, the lungs showed the highest retention of laninamivir, being 2680 pmol/g at 24 h post-dose. This retention level was 9.5-fold higher than that after a single administration of laninamivir itself (282 pmol/g, Fig. 3) . Furthermore, at 24 h after a single intranasal administration of [ Pharmacokinetic mechanism involved in such a preferable retention can be explained by a consecutive series of the following three steps: 1) uptake of LO from the airway
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This article has not been copyedited and formatted. The final version may differ from this version. localized in the cells, 3) trapping of the generated laninamivir within the cells due to its poor membrane permeability. First of all, the cellular uptake of LO is considered to be achieved by its lipophilic property, which is accomplished by introducing octanoyl moiety to the active form laninamivir. According to previous reports, inhaled compounds are generally absorbed by passive diffusion from the airway space into the circulating blood, and the absorption rate is increased with an increase in lipophilicity for compounds (Brown et al. 1983 , Tronde et al. 2003 . Furthermore, the absorption of lipophilic compounds is considered to be mediated primarily by membrane diffusion (Effros et al. 1983 ), whereas hydrophilic compounds appear to be absorbed by passive diffusion through the intercellular junction pores (Schneeberger, 1991) . In fact, the log D 7.4 of LO and laninamivir were −0.01 and < −2.18, respectively (unpublished data), therefore LO is likely to diffuse more easily into the airway epithelial cells, compared to laninamivir. On the other hand, the involvement of transporters in the pulmonary cellular uptake of LO has not been clarified yet; however, it is unlikely that any transporters contribute to the LO uptake, considering the result that no apparent saturation was observed in the LO uptake into primary cultured mouse airway epithelial cells even at the highest concentration tested (1000 μM, Fig. 5B ), which is close to the aqueous solubility of LO (approximately 0.6 mg/ml, corresponding to 1270 μM).
The drug concentration level in the airway space might also affect the drug amount observed in ELF. Actually, at 4 h after LO administration, the ELF concentration of LO was 348 pmol/ml, which was approximately 7-fold higher than that of laninamivir at the same time point after laninamivir administration (51.3 pmol/ml). This slow elimination would maintain high drug concentration exposing to the airway epithelial cells, leading to the increase of intracellular drug amounts. A possible factor for generating the different drug elimination rate in ELF between LO and laninamivir is considered to be paracellular transport. In the case of hydrophilic compounds, pulmonary absorption is thought to be accomplished by passive diffusion through tight junctions (Schneeberger, 1991) , as described above. Moreover, most exogenous macromolecules with a molecular weight less than 40 kDa are also thought to be absorbed from the airway space through tight junctions (Matsukawa et al. 1997 , Patton 1996 , and the absorption rate is inversely related to the molecular weight (Hastings et al. 1992 , Matsukawa et al. 1997 , Schanker et al. 1983 ).
From these reports, it is considered that the paracellular pathway has a significant role on air-to-blood transport, especially for hydrophilic compounds. As shown in Fig. 3 , soon after laninamivir administration, the plasma concentration of laninamivir increased in response to the rapid elimination in ELF, whereas the lung concentration of laninamivir was almost constant, not showing any considerable increase. These results support the finding that the laninamivir administered would pass through the circulating blood via paracellular pathway.
Furthermore, the intracellular hydrolysis plays an important role on the onset and duration of the pharmacological effect after LO administration. In addition to metabolic enzymes such as CYP enzymes and conjugation enzymes, esterase is currently known to be expressed in the respiratory tissues (Zhang et al. 2006 , Somers et al. 2007 ) and engage
This article has not been copyedited and formatted. The final version may differ from this version. et al. 1990 ) and ciclesonide (Nave et al. 2010 ). In the case of LO as well, hydrolysis in the respiratory tissues was observed both in vivo (Fig. 2 ) and in vitro (Fig. 5) , and a part of the LO diffused into the airway epithelial cells was continuously hydrolyzed to laninamivir during additional incubation in drug-free medium (Fig. 7) . In addition, the generated laninamivir was still present within the cells over 24 h (Fig. 7A) , possibly due to its poor membrane permeability. On compartmental kinetic analysis, k Lani (0.0707 h -1 ) was considerably lower than k Hydrolysis (0.561 h -1
, Table 2 ), indicating that a rate-limiting step for prolonged high retention of the generated laninamivir would be the membrane permeability, not the LO hydrolysis. This phenomenon was consistent with in vivo observation, in which laninamivir was generated rapidly after LO administration and A similar prodrug approach has been advocated by Bodor et al., for drug-targeting of blood-brain barrier (BBB). They showed that several hydrophilic compounds including opioid peptides were successfully delivered to the central nervous system by using specific prodrug approaches (Prokai et al. 1999 , Bodor et al. 2002 , Tapfer et al. 2004 ), one of which was to incorporate a lipophilic ester into the active form for the increase of permeability through BBB and the retention of the generated active form within the target site. Similarly, Pang and co-workers have suggested that there is a diffusional barrier that prevents enalaprilat from permeating across the hepatic cell membrane, whereas its ester prodrug enalapril easily crosses the cell membrane and then the generated active metabolite enalaprilat accumulate inside the cells (Pang et al. 1984 , de Lannoy et al. 1986 .
It is also demonstrated from our studies that this prodrug approach can be used for pulmonary acting drugs as well, especially in local administration via intranasal and/or inhaled route.
In summary, the prodrug LO administered intranasally to mice was transported into the airway epithelial cells by passive diffusion and efficiently converted/hydrolyzed to its active metabolite laninamivir. Subsequently, the generated laninamivir was retained within the cells over the long period by less penetration into the airway and/or systemic circulation due to its hydrophilic property. This could be one of the rational prodrug approaches for lung-targeting drug delivery and might be applicable for other pulmonary acting drugs.
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